Product Images Famotidine

This is a medication dosage guide for a drug used to treat various conditions such as active duodenal ulcer, active gastric ulcer, symptomatic nonerosive IGARD, erosive esophagitis, and other pathological hypersecretory conditions. The dosage recommendation varies depending on the condition, with instructions on recommended dosage for up to a certain number of weeks. There is also information on reduction of the risk of DU recurrence with a recommended daily dose for up to one year, or as clinically indicated.*

This is a description of a medication called Famotidine, USP that comes in 20 mg tablets and is available by prescription only. For full prescribing information, the package insert should be consulted. The tablets should be stored at a temperature of 20°C to 25°C in a light-resistant container with a child-resistant closure. The tablets are distributed by Teva Pharmaceuticals USA, Inc., manufactured for Wal-Mart and packaged by Legacy Pharmaceutical Packaging LLC.*

This is a medication called Famotidine, which comes in tablet form with each containing 40mg Famotidine, USP. The usual adult dosage is provided in the package insert, which also contains full prescribing information. The tablets should be stored at 20°C to 25°C and dispensed in a well-closed, light-resistant container with a child-resistant closure. This medication is only available with a prescription and should be kept out of the reach of children. The tablets are distributed by Wal-Mart and manufactured for Teva Pharmaceuticals USA, Inc., and packaged by Legacy Pharmaceutical Packaging LLC.*

This is a medication dosage guideline for several medical conditions. The recommended maximum dosages are specified based on the patient's creatinine clearance rate. It provides different dosages for active duodenal and gastric ulcers as well as for symptomatic nonerosive GERD and erosive esophagitis diagnosed by endoscopy. It also advises against the use of this medication for pathological hypersecretory conditions. Lastly, it recommends a specific dose for reducing the risk of DU recurrence.*

Famotidine is a medication taken at a dose of 20mg daily at bedtime, according to the given text. The only other information available is percentages for weeks two and four which are not clearly identified.*

This is a study that compares the effectiveness of Famotidine and a placebo on a sample of 149 people from the US and another sample of 294 people from an international study. The participants were assigned to receive either 40mg of Famotidine or a placebo at bedtime. The percentages indicate the number of people who had positive outcomes with Famotidine compared to the placebo. However, the specific outcomes and conditions being treated are not mentioned, so it is not possible to determine the significance of the results.*

This is a comparison of the effectiveness of Famotidine in 40 mg dose versus a placebo in 20 mg dose. The medication is taken twice daily before bedtime. The study involved 154 participants, with 73 in the placebo group. The effectiveness of the medication was evaluated at week 6, with 69% of participants in the Famotidine group reporting positive results compared to 62% in the placebo group.*

This appears to be a table showing the results of a study comparing the effectiveness of Famotidine with a placebo in reducing symptoms. Famotidine was given in a dosage of 40mg twice daily, while the placebo was given twice daily at a dosage of 20mg. The study involved 127 participants, with 66 in the placebo group. The table shows the percentage of participants who experienced a reduction in symptoms at week 6 and week 12 for both groups. At week 6, 48% of those taking Famotidine experienced a reduction in symptoms, compared to 18% in the placebo group. At week 12, 69% of those taking Famotidine experienced a reduction in symptoms, compared to 29% in the placebo group.*